TRP_1170x120_3-8-19

Joel Saban

Diplomat provides updated 2018 guidance and preliminary 2019 outlook

Diplomat provides updated 2018 guidance and preliminary 2019 outlook

FLINT, Mich. — Diplomat Pharmacy is updating its 2018 financial guidance and providing a preliminary 2019 outlook in connection with its presentation today at the JP Morgan Healthcare Conference in San Francisco. Diplomat now expects 2018 revenue to be at the lower end of the previously communicated $5.5 to $5.7 billion range and adjusted EBITDA to be at

Diplomat launches CastiaRx, leading specialty benefit manager

Diplomat launches CastiaRx, leading specialty benefit manager

FLINT, Mich. — Diplomat Pharmacy has unveiled CastiaRx to respond to industry demand for a leader in specialty benefit management. CastiaRx unites the full-service pharmacy benefit manager (PBM) capabilities of recently acquired LDI Integrated Pharmacy Services and National Pharmaceutical Services with Diplomat’s specialty pharmacy and infusion expertise. According to the IQVIA Institute for Human Data

Diplomat works to control specialty drug costs

Diplomat works to control specialty drug costs

FLINT, Mich. — Biosimilars, generic drugs and affordable branded drugs are top-of-mind at Diplomat Pharmacy Inc. this year as the specialty pharmacy looks to help health plans and patients rein in costs. According to Diplomat president Joel Saban, the surging market for expensive specialty drugs has put pressure on stakeholders across the health care sector.

Diplomat wraps up acquisition of LDI

Diplomat wraps up acquisition of LDI

FLINT, Mich. — Diplomat Pharmacy Inc. has closed its $595 million acquisition of pharmacy benefit manager LDI Integrated Pharmacy Services. With the completion of the cash-and-stock deal, Diplomat also announced that it has obtained $800 million in senior secured credit facilities. The proceeds of the debt financing will be used to finance the LDI acquisition, pay related transaction fees and

Peters appointed sales EVP at Diplomat

FLINT, Mich. — Robyn Peters has joined Diplomat Pharmacy in the role of executive vice president of sales and payor strategies. Peters, most recently vice president of market access and reimbursement at Biogen Inc., will oversee Diplomat’s payor and business development strategies, along with sales and pharma account management, and become a member of the

Diplomat Pharmacy buys LDI for $595 million

Diplomat Pharmacy buys LDI for $595 million

FLINT, Mich. — Diplomat Pharmacy Inc. plans to acquire St. Louis-based pharmacy benefit manager LDI Integrated Pharmacy Services for in a $595 million cash and stock deal. The move marks the second PBM acquisition this month by Diplomat, the nation’s largest independent specialty pharmacy. On Nov. 6, the company announced the purchase of National Pharmacy

Diplomat tabs former Biogen, Walgreens exec as EVP

Diplomat tabs former Biogen, Walgreens exec as EVP

FLINT, Mich. — Robyn Peters has joined Diplomat Pharmacy Inc. as executive vice president of sales and payor strategies. Peters, most recently vice president of market access and reimbursement at Biogen Inc., will oversee Diplomat’s payor and business development strategies, along with sales and pharma account management, and become a member of the specialty pharmacy’s executive

Saban to succeed Urick as Diplomat president

FLINT, Mich. — Diplomat Pharmacy recently announced the appointment of Joel Saban as the new company president. Paul Urick has decided to pursue other interests and will serve as president emeritus during a planned 90-day transition period. “During his tenure, Paul has served us in multiple leadership roles since he joined Diplomat with the acquisition

Joel Saban tabbed as Diplomat Pharmacy president

Joel Saban tabbed as Diplomat Pharmacy president

FLINT, Mich. — Diplomat Pharmacy Inc. has named Joel Saban as president, taking over from Paul Urick, who’s leaving the company to pursue other interests. The nation’s largest independent specialty pharmacy said late Monday that Urick will serve as president emeritus during a 90-day transition period. Saban had served as executive vice president of pharmacy